Pipeline and IP
XSpray’s projects are based on our proprietary hybrid nanoparticle technology (HyNapTM) that enables development of both improved and generic versions of PKI’s. We have a strong pipeline of PKI’s with soon to expire patent protection that can help the originator company with life cycle management or give generic companies an early access to the market. Three of our projects are currently in clinical development:
XS003 aims to increase bioavailability and improve safety of a marketed PKI product for the treatment of leukemia. XSpray has successfully conducted a clinical dose finding study and a clinical food effect study.
XS004 improved aims to minimize drug-drug interaction, increase bioavailability and reduce variability of a marketed PKI product for the treatment of leukemia. XSpray has successfully conducted a clinical dose finding study.
XS004 generic is an early access generic version of a marketed, multi-billion dollar PKI product for the treatment of leukemia.
XSpray pursues an active patent strategy that permits the company to protect its inventions and products on all significant markets. XSpray has granted and/or pending patents in several patent families in the areas of manufacturing technology and particle technology as well as product composition patents. Established collaboration is maintained with internationally renowned patent attorneys in Europe and in the US regarding patent applications and the maintenance and protection of patents.